Another bullet?
-
Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies. If safe and effective, it could become the first approved treatment against the disease.
The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir.
“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” said Kathleen Mullane, the University of Chicago infectious disease specialist overseeing the remdesivir studies for the hospital.
"Now look here, you Baltic gas passer... " - Mik, 6/14/08
The saying, "Lite is just one damn thing after another," is a gross understatement. The damn things overlap.
-
My first thought was Phase 3 with no control group?
So I looked up the study, it's 2400 people, randomized, 152(!) locations. Chicago just has preliminary results.
Entire study supposed to be done by May.
If the preliminary results are good enough, it'll get emergency approval.
https://clinicaltrials.gov/ct2/show/NCT04292899?term=remdesivir&cond=COVID&draw=2&rank=2
-
@George-K said in Another bullet?:
Remdesivir was one of the first medicines identified as having the potential to impact SARS-CoV-2, the novel coronavirus that causes Covid-19, in lab tests. The entire world has been waiting for results from Gilead’s clinical trials, and positive results would likely lead to fast approvals by the Food and Drug Administration and other regulatory agencies. If safe and effective, it could become the first approved treatment against the disease.
The University of Chicago Medicine recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those people, 113 had severe disease. All the patients have been treated with daily infusions of remdesivir.
“The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” said Kathleen Mullane, the University of Chicago infectious disease specialist overseeing the remdesivir studies for the hospital.
Keep shooting, folks. Somebody is bound to hit something...
-
Agreed. The market is...everyone on the planet. Science/tech will come through, likely ahead of schedule.
Of course my fear is something is rushed and the entire world is vaccinated with something that in 6 months turns out to be the trigger for The Walking Dead Season 1.
-
It’s why I’m skeptical the FDA will rush the vaccine too much, as opposed to an actual treatment.
The vaccine will be taken by billions of healthy people. Safety is no joke.
A treatment for severe cases is a different story, it’s a much smaller group, with much less to lose. We’ll see some record approvals in this space.
